Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Brokerages

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has been assigned a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.25.

Several equities research analysts have commented on the company. JMP Securities restated a “market outperform” rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Robert W. Baird cut their target price on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 26th. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. Finally, StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, February 19th.

Insiders Place Their Bets

In other Enanta Pharmaceuticals news, CEO Jay R. Luly bought 45,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average cost of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares of the company’s stock, valued at $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 13.89% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC increased its holdings in shares of Enanta Pharmaceuticals by 46.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 2,274 shares during the last quarter. AlphaQuest LLC increased its holdings in shares of Enanta Pharmaceuticals by 16.4% during the 4th quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares during the last quarter. Invesco Ltd. grew its holdings in Enanta Pharmaceuticals by 7.3% in the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock valued at $268,000 after buying an additional 3,186 shares in the last quarter. American Century Companies Inc. grew its holdings in Enanta Pharmaceuticals by 10.5% in the 4th quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 3,501 shares in the last quarter. Finally, US Bancorp DE grew its holdings in Enanta Pharmaceuticals by 4,933.7% in the 3rd quarter. US Bancorp DE now owns 4,329 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 4,243 shares in the last quarter. 94.99% of the stock is owned by institutional investors and hedge funds.

Enanta Pharmaceuticals Price Performance

NASDAQ:ENTA opened at $6.10 on Tuesday. Enanta Pharmaceuticals has a fifty-two week low of $4.71 and a fifty-two week high of $17.80. The stock has a market capitalization of $130.13 million, a PE ratio of -1.23 and a beta of 0.48. The business’s 50-day simple moving average is $6.22 and its 200-day simple moving average is $8.57.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 75.53% and a negative net margin of 157.57%. On average, research analysts expect that Enanta Pharmaceuticals will post -4.65 earnings per share for the current year.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.